Ripped 250 – Royal Pharmaceuticals
Ripped 250 by Royal Pharmaceuticals is a 250 mg/ml research-only injectable blend containing Testosterone Propionate (100 mg), Drostanolone Propionate (50 mg) and Trenbolone Acetate (50 mg). Designed for intramuscular depot studies, this short-ester AAS combination is used in research exploring androgen signalling, nitrogen retention, erythropoiesis and metabolic effects. Not for human or veterinary use.
€ 69.00
Beskrivelse
Ripped 250 – Royal Pharmaceuticals (Research-Grade AAS Blend)
Category: Injectable Anabolic-Androgenic Steroid Blend (Research Only)
Brand: Royal Pharmaceuticals
Strength: 250 mg/ml total (Test P 100 mg, Mast P 50 mg, Tren A 50 mg)
Packing: 10 × 1 ml ampoules
Origin: United Kingdom
Pris: €69
Use Notice: For laboratory and analytical research only — not for human or veterinary administration.
🧪 What is Ripped 250?
Ripped 250 is a fixed-combination injectable consisting of three short-acting anabolic–androgenic steroid esters:
- Testosterone Propionate – 100 mg
- Drostanolone Propionate (Masteron P) – 50 mg
- Trenbolone Acetate – 50 mg
Short-chain esters create rapid release from the intramuscular depot, making this blend suitable for research requiring frequent sampling intervals or tight control of androgen exposure.
🔬 Key Technical Characteristics
- Pharmacological class: Anabolic-androgenic steroids (AAS)
- Route: Intramuscular injection
- Ester types: Propionate (Test/Mast) and acetate (Tren)
- Approximate half-lives: Test P ~2 days, Mast P ~2 days, Tren A ~2–3 days
- WADA status: All components are prohibited at all times under “Anabolic Agents”.
🧬 Mechanism of Action
Testosterone Propionate
- Esterified form of endogenous testosterone
- Promotes protein synthesis, nitrogen retention and erythropoiesis
- Aromatises to estradiol and converts to DHT
Drostanolone Propionate (Masteron P)
- DHT-derived androgen with no aromatisation
- Strong AR binding; low water-retention profile
- May exhibit mild anti-estrogenic action at receptor level
Trenbolone Acetate
- 19-nor testosterone derivative with extremely high AR affinity
- Does not aromatise; interacts with progesterone receptors
- Associated with strong anabolic effects and reduced glucocorticoid signalling
Together, these compounds produce additive or synergistic effects on androgen-mediated pathways while also accumulating their individual risk profiles.
📚 Research Overview
- Testosterone esters — studied extensively in hypogonadism, lean-mass changes, bone density and hematology.
- Drostanolone — historically investigated in hormone-responsive breast cancer; displays typical DHT-like androgenic behaviour.
- Trenbolone — widely documented in veterinary models; shows powerful anabolic, neuroendocrine, and metabolic effects.
Ripped 250 as a combined formulation lacks clinical trial data; research is based on extrapolation from individual components.
📈 Potential Research-Level Observations
- Enhanced protein synthesis and nitrogen retention
- Marked changes in red blood cell mass and hemoglobin
- Reduced fat mass and altered nutrient partitioning (trenbolone-related)
- Increased muscle density and tissue “hardness” in controlled models
These findings apply only to research settings and do not imply suitability for unsupervised use.
⚠️ Risk Profile & Possible Adverse Effects
Endocrine & Reproductive
- Suppression of LH/FSH and endogenous testosterone
- Testicular atrophy, reduced sperm count, infertility
- Virilisation and menstrual disruption in females
Cardiovascular & Metabolic
- Reduced HDL, increased LDL
- Hypertension, fluid retention (via testosterone)
- Increased risk of thrombotic or cardiovascular events
- Polycythaemia (elevated hematocrit)
Hepatic & Renal
- Potential hepatic strain despite being non-oral injectables
- Renal stress secondary to blood-pressure alteration
Neuropsychiatric
- Mood instability, irritability, anxiety
- Insomnia or reduced impulse control
Other
- Acne, seborrhoea, androgenic alopecia
- Injection-site pain or infection
- Gynecomastia risk due to testosterone aromatisation combined with trenbolone’s progestogenic action
🛑 Compliance & Regulatory Notice
- All three ingredients are controlled/prescription-only substances in many jurisdictions.
- WADA prohibits testosterone, drostanolone and trenbolone in- and out-of-competition.
- Analytical detection windows vary depending on dose and duration.
- This product is supplied strictly for laboratory and analytical research — not for therapeutic or recreational use.
📊 Technical Data Table
| Parameter | Test P | Mast P | Tren A |
|---|---|---|---|
| Chemical class | Androgen / AAS | DHT-derived AAS | 19-nor AAS |
| Concentration (mg/ml) | 100 mg | 50 mg | 50 mg |
| Ester | Propionate | Propionate | Acetate |
| Aromatisation | Yes | No | No (progestogenic) |
| Halveringstid | ~2 days | ~2 days | ~2–3 days |
| Main receptor | AR, aromatase (indirect) | Androgen receptor | AR & progesterone receptors |
| WADA status | Prohibited | Prohibited | Prohibited |
For laboratory research only — not for human or veterinary use.
Der er ingen anmeldelser endnu.
